Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
New Pharma Vision to Set Out Clear Goal, KPIs after Lawmaker Calls
The Ministry of Health, Labor and Welfare (MHLW) plans to add a clear goal and key performance indicators (KPIs) to its new pharmaceutical industry vision due out later this month in a move responding to lawmakers’ calls. The vision will…
To read the full story
Related Article
- Japan Unveils New Pharma Industry Vision, 1st Update in 8 Years
September 14, 2021
- Pharma Leaders Support Draft Industry Vision, but Stress Need for Price Maintenance of Patented Meds: Confab
August 25, 2021
- Public-Private Dialogue for New Pharma Vision Set for Aug. 24
August 18, 2021
- Lawmakers See No Ultimate Goal in New Pharma Industry Vision
August 6, 2021
- New Pharma Industry Vision to Push Predictability for Investment Recovery: Draft Outline
August 3, 2021
REGULATORY
- Ishin Proposes Adding Drug, Device Makers to Chuikyo, LDP Wary
June 10, 2026
- Cabinet Approves Immunization Act Revision to Cover Antibody Drugs
June 10, 2026
- LDP Lawmakers Seek Routine HPV Vaccinations for Males by April 2027
June 10, 2026
- LDP Team Seeks Minister-Led AI Task Force at MHLW
June 10, 2026
- MHLW to Continue Reviewing Tavneos Safety Measures: Official
June 10, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…